<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-89 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-89</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-89</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-5.html">extraction-schema-5</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <p><strong>Paper ID:</strong> paper-781c2a94a79681aefbd2424cc597edb31a6f428d</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/781c2a94a79681aefbd2424cc597edb31a6f428d" target="_blank">Non-small cell lung cancer: current treatment and future advances.</a></p>
                <p><strong>Paper Venue:</strong> Translational Lung Cancer Research</p>
                <p><strong>Paper TL;DR:</strong> Current treatments including surgery, chemotherapy, radiotherapy, and immunotherapy are discussed as well as how biomarker testing has helped improve survival in patients with NSCLC.</p>
                <p><strong>Cost:</strong> 0.029</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e89.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e89.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Smoking dose / exposure metrics</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cigarette smoking dose and exposure metrics (years smoked, packs/day, pack-years, passive smoking)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Epidemiologic measures of tobacco exposure that strongly determine lung cancer risk (years of smoking, packs/day, pack-years) and include passive smoking (secondhand). The paper emphasizes dose–response (more years or more packs/day → higher risk) and reports passive smoking RRs and Surgeon General estimates.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Epidemiology / review of cohort and case-control studies</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Mixed populations summarized in review; smokers and nonsmokers across multiple studies and geographies (specific cohorts not detailed in this review).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Reported qualitatively as 'number of years' and 'number of packs smoked per day' and pack-years; passive smoking reported with pooled relative risks (meta-analysis range 1.14–5.20) and Surgeon General estimate of 20–30% increased risk for nonsmokers living with a smoker.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Incident lung cancer and lung cancer mortality as reported in referenced epidemiologic studies and meta-analyses (ascertainment methods vary by source; not harmonized in review).</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>['Passive smoking (secondhand smoke) — increases risk in nonsmokers and contributes to exposure heterogeneity; cigarette filter use associated with deeper inhalation/topography shifting lesion location (peripheral adenocarcinoma).']</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Passive smoking relative risk range reported 1.14–5.20 (meta-analysis) and Surgeon General estimate of ~20–30% increased lung cancer risk for nonsmokers living with a smoker. Review states 'increases in the number of years or the number of packs smoked per day increases the degree of risk for lung cancer' and that smoking causes at least 80% of lung cancer deaths.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Higher cumulative dose increases mutational burden and probability of malignant transformation; changes in inhalation topography (filters → deeper inhalation) alter deposition and lesion location.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Exposure measurement heterogeneity across studies (self-report), potential misclassification of intensity/duration, and confounding by occupational and environmental co-exposures noted in review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e89.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>15q25 / nicotinic receptor locus</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Chromosome 15q25 nicotinic acetylcholine receptor locus (CHRNA5-CHRNA3-CHRNB4 region)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A susceptibility locus identified in multiple genetic studies that contains genes encoding subunits of the nicotinic acetylcholine receptor; variants at this locus associate with nicotine dependence and increased lung cancer risk, with dose-dependent effect sizes reported in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A variant associated with nicotine dependence, lung cancer and peripheral arterial disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Genetic association studies / GWAS (three independent genetic studies referenced)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Populations from the three independent genetic studies summarized by the review (specific ancestries not specified here but original refs include large case-control cohorts analyzed in refs 28–30).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Not uniformly reported in review; locus is discussed as related to nicotine dependence (hence smoking intensity/duration) rather than a specific metric in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Association with lung cancer incidence in genetic association studies (case-control / GWAS designs referenced).</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene_or_variant': 'CHRNA5-CHRNA3-CHRNB4 locus (chromosome 15q25)', 'rsID': None, 'direction_of_effect': 'Risk-increasing (allele count associated with higher lung cancer risk)', 'notes_on_smoker_specificity': 'Association may act partly via increased nicotine dependence / smoking intensity; reviewed as increasing lung cancer risk in carriers.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[{'interaction_description': 'Variant at 15q25 affects nicotine dependence which influences smoking exposure (dose), thereby increasing lung cancer risk; interaction is mechanistic (gene → behavior → exposure).', 'interaction_model': 'Not specified (mediated interaction described conceptually rather than formal additive/multiplicative model).', 'summary': 'Review states people with one copy have ~30% increased risk and with two copies have ~70–80% increased risk of lung cancer, implying dose-response with allele count and likely mediation through smoking behavior.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>['Nicotine dependence / smoking intensity (mediator of genetic effect)']</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Per review: carriers of one copy of the marker have ~30% increased risk of developing lung cancer; carriers of two copies have ~70–80% increased risk (figures reported from three independent studies summarized in review).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Variants in nicotinic receptor genes increase nicotine dependence, leading to higher cumulative exposure to tobacco carcinogens and therefore higher lung cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Review does not provide rsIDs or detailed population stratification; it is unclear how much of the genetic effect is independent of measured smoking intensity versus mediated by it.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e89.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TP53 germline</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Germline TP53 sequence variations (p53)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Inherited (germline) variants in TP53 are associated with markedly increased lung cancer risk in carriers who smoke, indicating strong gene × smoking interaction for cancer predisposition.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Genetic / family study (analysis of germline p53 mutation carriers)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Germline TP53 mutation carriers referenced in review (study population details in ref. 27; review does not enumerate sample size here).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Interaction described between germline p53 status and smoking; specifics of dose metrics not provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Lung cancer occurrence in germline TP53 mutation carriers versus non-smokers (as reported in referenced study).</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene_or_variant': 'TP53 germline sequence variations', 'rsID': None, 'direction_of_effect': 'Markedly increased risk among carriers who smoke (risk-increasing)', 'notes_on_smoker_specificity': 'Effect specifically highlighted for carriers who also smoke versus nonsmokers.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[{'interaction_description': 'Germline TP53 variant × cigarette smoking — carriers who smoke have substantially higher lung cancer risk compared with nonsmokers.', 'interaction_model': "Not specified (reported as multiplicative increase: 'more than 3 times more likely' in review).", 'summary': 'Review states carriers of TP53 germline variations who also smoke are >3× more likely to develop lung cancer than nonsmokers (reference 27).'}]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>['TP53 germline (tumor suppressor / genomic stability regulator) — implicates deficient genomic surveillance in higher susceptibility.']</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Review reports TP53 germline carriers who smoke are 'more than 3 times more likely to develop lung cancer than nonsmokers' (from referenced study).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Inherited loss of TP53-mediated tumor suppression increases susceptibility to tobacco-induced mutagenesis, producing a multiplicative effect with smoking.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Original study details (sample size, ascertainment) not given in review; potential confounding by other familial/environmental exposures not detailed here.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e89.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Radon exposure</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Residential radon exposure</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Indoor radon (a naturally occurring radioactive gas) is identified as a lung cancer risk factor and has been linked to ~21,000 U.S. lung cancer deaths; pooled case-control analyses show increased incidence at certain radon levels.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Pooled case-control analyses / meta-analyses referenced</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>North American, European, and Chinese residential populations included in pooled analyses and collaborative studies cited (refs 16–18).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Radon exposure reported as pCi/L (review cites increased incidence linked to residential radon levels of 2.7 pCi/L); smoking not quantified in these summaries though radon risk can interact with smoking in primary literature.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Lung cancer incidence/mortality ascertained via case-control studies and pooled analyses referenced in review.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>['Residential location, housing basement exposure (radon accumulation) — environmental modifier of risk among smokers and nonsmokers.']</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Review notes increased lung cancer linked to residential radon exposure levels around 2.7 pCi/L and attributes ~21,000 US lung cancer deaths to radon exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Radon decay products cause DNA damage in bronchial epithelium contributing to carcinogenesis; combined burden with tobacco smoke increases overall risk.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Review summarizes pooled studies; detailed interaction estimates with smoking not provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e89.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Asbestos & occupational carcinogens</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Asbestos and other occupational exposures (arsenic, beryllium, cadmium, silica, nickel compounds, diesel exhaust, etc.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Occupational exposures that increase lung cancer risk and may explain heterogeneity among smokers depending on co-exposures; asbestos fiber dimension linked to mortality risk.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Occupational epidemiology / cohort and case-control studies (reviewed)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Workers exposed in industrial or manufacturing occupations; specific cohorts not enumerated in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Smoking discussed generally as a co-exposure; specific metrics not provided for interaction estimates in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Lung cancer and mesothelioma incidence and mortality in occupational cohorts (as summarized from refs 19–23).</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>['Occupational exposure history (asbestos, arsenic, silica, diesel exhaust, etc.) — acts as a modifier or confounder of smoking-related lung cancer risk.']</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Review references studies showing increased lung cancer risk linked to asbestos and other occupational carcinogens; fiber size is reported as predictive of mortality (no single effect size quoted in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Co-exposure to industrial carcinogens increases total carcinogen dose and may act synergistically with tobacco smoke to raise lung cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Heterogeneity of exposure assessment in occupational studies; potential residual confounding by smoking intensity.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e89.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Air pollution / PAHs</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Ambient air pollution and polycyclic aromatic hydrocarbons (PAHs)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Long-term exposure to traffic-related air pollution (including PAHs and fine particulate matter) is associated with modestly increased lung cancer mortality and may modify risk among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Epidemiologic cohort studies / environmental health studies (referenced)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Residents of urban/traffic-congested areas in cohort studies (detailed cohorts are those in referenced literature such as ref 25).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Air pollution exposure measured as long-term accumulated exposure to fine particulates and traffic emissions; smoking discussed separately.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>All-cause lung cancer mortality in long-term exposure studies (referenced cohort studies).</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>['Residential and occupational exposure to ambient air pollution and PAHs — environmental modifiers that can add to tobacco-related carcinogen burden.']</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Review cites an ~8% increased risk of all-cause lung cancer mortality associated with air pollution exposure (ref 25).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Ambient carcinogens (PAHs, particulates) add to cumulative genotoxic exposure and may interact with tobacco smoke to raise lung cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Potential confounding by smoking behavior and other exposures; exposure assessment variability across studies.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e89.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR mutation (somatic)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor (EGFR) activating somatic mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Somatic activating EGFR mutations (exons 18–21, most commonly exon 19 deletions and L858R) define a molecular subset of NSCLC enriched in never-smokers and predict response to EGFR tyrosine kinase inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Molecular epidemiology / tumor genomics</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>EGFR mutations noted in 10–15% of lung adenocarcinomas in European and Asian descent, and enriched in never-smokers and females as summarized by the review.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>EGFR mutation prevalence inversely associated with smoking (more common in never-smokers); specific exposure strata not given.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Tumor genotype (EGFR mutation status) in NSCLC patients; clinical outcomes referenced relate to response to EGFR inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene_or_variant': 'EGFR somatic activating mutations (exon 19 deletions, L858R in exon 21)', 'rsID': None, 'direction_of_effect': 'Not a germline risk variant; somatic mutations define tumor subsets associated with lower smoking exposure (more common in never-smokers).', 'notes_on_smoker_specificity': 'EGFR-mutant tumors are more frequent in never-smokers, implying that smokers are less likely to develop EGFR-driven tumors and suggesting heterogeneity in tumorigenic pathways by smoking status.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['EGFR mutations are largely non-overlapping with KRAS and ALK alterations and are enriched in never-smokers; this indicates different molecular pathways depending on smoking exposure.']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Review reports EGFR mutations present in ~10–15% of lung adenocarcinomas in European and Asian-descent populations and are enriched in never-smokers; EGFR mutation-positive tumors show ~70% response rate to erlotinib/gefitinib (clinical response, not susceptibility estimate).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Different carcinogenic pathways: tumors in never-smokers are more often driven by EGFR activating mutations rather than tobacco-induced mutations, explaining heterogeneity in which smokers vs never-smokers develop certain tumor types.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Somatic mutation prevalence is descriptive of tumors and does not directly quantify germline susceptibility among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e89.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS mutation (somatic)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS oncogenic somatic mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>KRAS missense mutations (commonly at codons G12/G13) are more frequent in lung adenocarcinomas of smokers and define a molecular subset that is largely non-overlapping with EGFR/ALK alterations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>KRAS mutations in non-small cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Molecular epidemiology / tumor genomics</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>KRAS mutations identified more frequently in adenocarcinomas, Caucasians, and individuals with a smoking history; prevalence estimates ~10–25% in adenocarcinoma per review.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Association described qualitatively as linked to smoking history; no explicit pack-year thresholds provided.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Tumor KRAS mutation status in NSCLC patients (genotyping of tumor tissue).</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene_or_variant': 'KRAS somatic mutations (codons 12, 13, 61; e.g., G12C)', 'rsID': None, 'direction_of_effect': 'Somatic driver mutations enriched in tumors from smokers (risk of KRAS-mutant tumors higher in smokers).', 'notes_on_smoker_specificity': 'KRAS-mutant tumors are more common in smokers, consistent with tobacco mutagenesis shaping tumor genotype.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['KRAS-mutant tumors often occur in smokers and are mutually exclusive with EGFR/ALK alterations; specific KRAS subtypes (e.g., G12C) are common in smokers.']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Review cites KRAS present in ~10–25% of adenocarcinomas and notes enrichment in smokers; no direct OR/HR contrasting smokers by KRAS status provided.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>['KRAS mutations have limited predictive role for EGFR tyrosine kinase inhibitor response or cytotoxic chemotherapy per review.']</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Tobacco carcinogens produce characteristic mutations (e.g., KRAS) leading to specific oncogenic driver profiles in tumors arising in smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Tumor-based somatic mutation data do not by themselves explain predisposition; they reflect carcinogenic processes after initiation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e89.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ALK rearrangements (EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Anaplastic lymphoma kinase (ALK) rearrangements, notably EML4-ALK fusions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ALK gene fusions (e.g., EML4-ALK) define a molecular subset of NSCLC enriched in younger patients and never/light smokers and are largely non-overlapping with EGFR and KRAS mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Molecular discovery / tumor genomics</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>ALK rearrangements occur in ~3–7% of lung tumors, more common in younger patients and those who never smoked or were light smokers (per review).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>ALK-positive tumors reported as more common in never-smokers or light smokers; detailed exposure metrics not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Tumor ALK-rearrangement status in NSCLC patients (molecular pathology).</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene_or_variant': 'EML4-ALK fusion and other ALK rearrangements (e.g., KIF5B-ALK, TFG-ALK)', 'rsID': None, 'direction_of_effect': 'Somatic fusion events defining tumor subtype; enriched in never/light smokers (inverse association with heavy smoking).', 'notes_on_smoker_specificity': 'ALK rearrangements are associated with younger age and minimal smoking history.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['ALK-rearranged tumors tend to occur in never/light smokers and do not overlap with other driver mutations common in smokers.']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Review reports ALK rearrangements in ~3–7% of lung tumors and presents trial outcome data (crizotinib PFS 10.9 vs 7 months) but not susceptibility ORs among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Distinct molecular oncogenic events (fusion-driven) underlie tumors occurring in patients with minimal smoking exposure, illustrating heterogeneity in pathways to lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Somatic nature of ALK fusions means they are tumor features rather than germline susceptibility markers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e89.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF somatic mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Somatic BRAF mutations occur in a small proportion (~1–4%) of NSCLC, are most common in adenocarcinomas and have been linked more often to former/current smokers in some studies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Molecular epidemiology / tumor genomics</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Patients with lung adenocarcinoma; review cites a study of 697 patients where ~3% harbored BRAF mutations (V600E, G469A, D594G).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>BRAF mutations described as more commonly linked with former/current smokers; no detailed exposure quantiles provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Tumor BRAF mutation status among NSCLC adenocarcinoma cases.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[{'gene_or_variant': 'BRAF somatic mutations (e.g., V600E, G469A, D594G)', 'rsID': None, 'direction_of_effect': 'Somatic driver mutations observed more frequently in tumors from former/current smokers in referenced studies.', 'notes_on_smoker_specificity': 'Association described qualitatively in review.'}]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['BRAF-mutant tumors are largely non-overlapping with other oncogenic mutations and have a distribution that includes smokers.']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>In a study of 697 lung adenocarcinoma patients cited, 3% had BRAF mutations with variant breakdown (V600E 50%, G469A 39%, D594G 11%); review notes linkage to smoking history but provides no ORs.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Tobacco-related mutagenesis may generate BRAF alterations in a subset of tumors arising in smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Low frequency limits power for precise effect estimates; somatic mutation data reflect tumor phenotype more than pre-diagnostic susceptibility.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e89.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Cigarette filter / inhalation topography</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cigarette filter use leading to altered inhalation depth (topography)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Introduction of cigarette filters is hypothesized to produce deeper inhalation of smoke, shifting deposition to peripheral lung regions and contributing to increased peripheral adenocarcinomas.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Epidemiologic observation / hypothesis</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>General smoker populations; review references historic changes in cigarette design and histologic shifts in lung cancer subtypes.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td>Not quantified; concept refers to changes in inhalation depth/topography due to filter use rather than packs/day.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Histologic subtype distribution (peripheral adenocarcinoma incidence) cited as outcome.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>['Cigarette design (filter presence) alters smoker behavior and inhalation patterns, a behavioral/environmental modifier of deposition and risk.']</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>['Peripheral adenocarcinoma increase hypothesized to be related to deeper inhalation with filters.']</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Review cites hypothesis linking filter use to peripheral lesion distribution but provides no quantified risk estimates.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Filter-induced deeper inhalation increases delivery of smaller particles to peripheral airways (type II alveolar cells), potentially altering where carcinogenesis occurs and which smokers develop peripheral adenocarcinomas.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Mechanistic hypothesis based on epidemiologic correlations; direct measurements of inhalation depth and deposition by filter use not provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e89.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Immune / tumor microenvironment markers</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Immune infiltration and checkpoint ligand expression (CD4+, CD8+, NK cells, dendritic cells, PD-L1, MUC1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Tumor immune microenvironment markers (high CD4+/CD8+/NK/dendritic cell infiltration, PD-L1 expression, MUC1 overexpression) are linked to prognosis and response to immunotherapy and may reflect host surveillance differences that influence which smokers develop clinically significant tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Immuno-oncology / biomarker studies summarized in review</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>NSCLC patients in immunotherapy and biomarker studies (specific cohorts referenced in cited immunology literature).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Associations reported mainly with survival and response to immunotherapies (e.g., nivolumab, MK-3475) and with presence of intratumoral lymphoid structures.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>['PD-L1 tumor expression (used to select patients for MK-3475) and MUC1 overexpression (target for vaccines) are tumor markers discussed; intratumoral lymphoid structures and numbers of CD4+/CD8+/NK cells correlate with survival.']</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>['TGF-β2 levels discussed in vaccine context as immunosuppressive and correlated with outcomes; elevated TGF-β2 suppresses NK and dendritic cell function.']</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Review notes higher numbers of CD4+, CD8+, NK, and dendritic cells are associated with better patient survival (no specific effect sizes given); MK-3475 trial reported response rates among PD-L1+ patients (overall response 36% across groups in a small trial).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Variation in host immune surveillance and tumor immune evasion (e.g., PD-L1 expression, TGF-β2-mediated immunosuppression) may determine whether carcinogenic exposure leads to clinically manifest cancer versus immune elimination.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Most immune markers discussed relate to prognosis and treatment response rather than pre-diagnostic susceptibility among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e89.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Serum EGF / anti-EGF antibody response</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Serum epidermal growth factor (EGF) levels and anti-EGF antibody response (CIMAvax vaccine data)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>In vaccine trials, baseline serum EGF and the magnitude/duration of anti-EGF antibody response correlated with survival after vaccination; lower serum EGF and higher antibody titers associated with longer survival.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Immunotherapy clinical trials / biomarker correlates</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Patients with stage IIIB/IV NSCLC after first-line chemotherapy (n=80 in referenced phase II trial); vaccine recipients stratified by antibody response and baseline EGF levels.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Overall survival in advanced NSCLC clinical trial (vaccine vs BSC).</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[{'biomarker': 'Serum EGF', 'tissue': 'Blood (serum)', 'relation_to_risk_or_outcome': 'Vaccinated patients with baseline serum EGF <168 pg/mL had longer median overall survival (13 months) versus those with >168 pg/mL (5.6 months); good antibody responders (titer >1:4,000) had longer median OS (11.7 vs 3.6 months).'}]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>Good antibody responders (titer >1:4,000) had median OS 11.7 months vs 3.6 months for poor responders; baseline serum EGF <168 pg/mL associated with median OS 13 months vs 5.6 months for >168 pg/mL in vaccinated patients (phase II trial data reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Lower circulating EGF or strong anti-EGF immune response may reduce tumor growth signaling and correlate with better survival; these are prognostic/theragnostic markers rather than pre-diagnostic susceptibility metrics.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Findings are from vaccinated populations and concern post-diagnosis prognosis/response; not direct evidence for pre-diagnostic susceptibility among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e89.13">
                <h3 class="extraction-instance">Extracted Data Instance 13 (e89.13)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that explain inter-individual variation in lung cancer risk among smokers (i.e., why only some smokers develop lung cancer), including genetic susceptibility, gene–environment interactions, exposure/dose metrics, comorbid lung disease, molecular/epigenetic biomarkers, and study-reported effect sizes comparing higher- vs lower-risk smoker subgroups.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vaccine trial nulls / negative findings</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Negative or null phase III vaccine trial outcomes (MAGE-A3 MAGRIT, belagenpumatucel-L overall, L-BLP25 START)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Large phase III vaccine trials failed to meet primary endpoints in the overall populations, illustrating difficulty in translating biomarker-driven immunotherapy to improved population-level outcomes and highlighting heterogeneity in treatment effects/subgroups.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>MAGRIT</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Clinical trials (phase III) with biomarker-stratified components</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Resected NSCLC patients (MAGRIT n=2,270 stage IB–IIIA); belagenpumatucel-L phase III included 532 patients post-chemotherapy; L-BLP25 START included 1,513 unresectable stage III patients after chemoradiotherapy.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_exposure_metrics</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_outcome_definition</strong></td>
                            <td>Disease-free survival and overall survival endpoints in adjuvant and maintenance vaccine trials.</td>
                        </tr>
                        <tr>
                            <td><strong>host_genetic_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>gene_environment_interactions</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>polygenic_or_risk_scores</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>carcinogen_metabolism_biomarkers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>dna_repair_and_genomic_stability_factors</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>epigenetic_and_transcriptomic_markers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>preexisting_lung_disease_and_inflammation</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_and_social_modifiers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>tumor_molecular_features_in_smokers</strong></td>
                            <td>[]</td>
                        </tr>
                        <tr>
                            <td><strong>risk_estimates_key_results</strong></td>
                            <td>MAGRIT (MAGE-A3) did not improve disease-free survival vs placebo in overall population; belagenpumatucel-L phase III did not meet primary endpoint (median OS vaccine 20.3 vs placebo 17.8 months; HR 0.94; P=0.594), though subgroup randomized within 12 weeks showed improved OS (20.7 vs 13.7 months; HR 0.75; P=0.083). START (L-BLP25) failed primary endpoint overall though subgroup receiving concurrent chemo-radiation showed survival advantage.</td>
                        </tr>
                        <tr>
                            <td><strong>predictive_model_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>negative_or_null_findings</strong></td>
                            <td>['MAGRIT (phase III) — no increase in disease-free survival with MAGE-A3 adjuvant therapy (overall population).', 'Belagenpumatucel-L phase III — did not meet primary endpoint (HR 0.94; P=0.594) though subgroup signals reported.', 'START (L-BLP25) — primary endpoint not met; subgroup benefit with concurrent chemoradiation.']</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanistic_explanations</strong></td>
                            <td>Heterogeneous immune competence, timing relative to chemotherapy/radiation, and patient selection (biomarker-defined subgroups) may underlie variable vaccine efficacy across patients.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_confounders</strong></td>
                            <td>Negative overall trial results caution against assuming broad predictive utility of single biomarkers; subgroup analyses may be exploratory and underpowered.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>A variant associated with nicotine dependence, lung cancer and peripheral arterial disease <em>(Rating: 2)</em></li>
                <li>A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 <em>(Rating: 2)</em></li>
                <li>Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 <em>(Rating: 2)</em></li>
                <li>Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk <em>(Rating: 2)</em></li>
                <li>Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies <em>(Rating: 2)</em></li>
                <li>Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution <em>(Rating: 2)</em></li>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>KRAS mutations in non-small cell lung cancer <em>(Rating: 2)</em></li>
                <li>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer <em>(Rating: 2)</em></li>
                <li>Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>